CNBX Pharmaceuticals Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-314.0K | $-695.2K | $-3.7M | $-3.7M | $-3.2M | $-7.5M | $1.1M | $-3.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $0 | $72.3K | $162.1K | $198.5K | $220.9K | $215.2K | $188.9K | $88.4K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $0 | $139.7K | $180.5K | $728.9K | $0 | — | — | — |
| Net Cash from Operating Activities | $-171.3K | $-244.3K | $-112.5K | $-1.7M | $-2.5M | $-2.8M | $-3.1M | $-2.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $113.5K | $24.7K | $25.2K | $645.0K | $3.3M | $-5.3M | $-1.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $160.0K | $27.5K | $100.0K | $389.9K | $2.5M | $0 | $7.2M | $1.4M |
| Net Change in Cash | — | — | — | — | — | $511.6K | $-1.1M | $-2.0M |
| Free Cash Flow | — | — | — | — | — | — | — | — |